Source:http://linkedlifedata.com/resource/pubmed/id/20561593
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0002874,
umls-concept:C0005767,
umls-concept:C0005961,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0043227,
umls-concept:C0178602,
umls-concept:C0205082,
umls-concept:C0239307,
umls-concept:C0439661,
umls-concept:C0445356,
umls-concept:C0935850,
umls-concept:C1180059,
umls-concept:C1257890,
umls-concept:C1518904,
umls-concept:C1563350,
umls-concept:C1563351,
umls-concept:C2603343
|
| pubmed:issue |
1
|
| pubmed:dateCreated |
2011-1-4
|
| pubmed:abstractText |
Information is scarce on outcomes after unrelated cord blood transplantation (UCBT) for patients with severe aplastic anemia (SAA). We retrospectively analyzed 71 patients (median age, 13 years; 28 adults) with SAA (9 with paroxysmal nocturnal hemoglobinuria [PNH]) who received a single-unit (n = 57; 79%) or double-unit UCBT (n = 14; 19%) in 32 centers between 1996 and 2009. A reduced-intensity conditioning regimen was provided in 68% of the patients. The cumulative incidence (CI) of neutrophil recovery was 51% ± 6% at day 60, with significantly better engraftment seen in recipients of higher prefreezing total nucleated cell (TNC) dose (>3.9 10(7)/kg; hazard ratio [HR], 1.5; P = .05). The CI of platelet engraftment at day 180 posttransplantation was 37% ± 7%, that of grade II-IV acute GVHD was 20% ± 5%, and that of chronic GVHD at 3 years was 18% ± 5%. At a median follow-up of 35 months (range, 3-83 months), the estimated probability of 3-year overall survival (OS) was 38% ± 6%. Significantly improved OS was seen in recipients of >3.9 10(7) TNCs/kg prefreezing (45%, compared with 18% for recipients of ? 3.9 10(7) TNC/kg; HR, 0.4; P = .007). These results highlight the fundamental role of cell dose for both engraftment and OS in patients with SAA undergoing UCBT.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1523-6536
|
| pubmed:author |
pubmed-author:AljurfMahmoudM,
pubmed-author:BonfimCarmenC,
pubmed-author:GandemerVirginieV,
pubmed-author:GerardMichelM,
pubmed-author:GluckmanElianeE,
pubmed-author:KurtzbergJoanneJ,
pubmed-author:MaurySebastienS,
pubmed-author:PasswegJakobJ,
pubmed-author:Peffault de LatourRegisR,
pubmed-author:PurtillDuncanD,
pubmed-author:RochaVandersonV,
pubmed-author:RuggeriAnnalisaA,
pubmed-author:SanzGuillermoG,
pubmed-author:SociéGerardG
|
| pubmed:copyrightInfo |
2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
78-85
|
| pubmed:meshHeading |
pubmed-meshheading:20561593-Adolescent,
pubmed-meshheading:20561593-Anemia, Aplastic,
pubmed-meshheading:20561593-Cell Count,
pubmed-meshheading:20561593-Cord Blood Stem Cell Transplantation,
pubmed-meshheading:20561593-Graft Survival,
pubmed-meshheading:20561593-Graft vs Host Disease,
pubmed-meshheading:20561593-Humans,
pubmed-meshheading:20561593-Platelet Count,
pubmed-meshheading:20561593-Retrospective Studies,
pubmed-meshheading:20561593-Survival Rate,
pubmed-meshheading:20561593-Young Adult
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation.
|
| pubmed:affiliation |
Bone Marrow Transplant Unit, Saint Louis Hospital, Paris, France. regis.peffaultdelatour@sls.aphp.fr
|
| pubmed:publicationType |
Journal Article,
Multicenter Study
|